首页> 外文期刊>International journal of biological sciences >Diagnostic, progressive and prognostic performance of m sup6/sup A methylation RNA regulators in lung adenocarcinoma
【24h】

Diagnostic, progressive and prognostic performance of m sup6/sup A methylation RNA regulators in lung adenocarcinoma

机译:m 6 肺腺癌中甲基化RNA调节剂的诊断,渐进性和预后性能

获取原文
           

摘要

Background: N6-methyladenosine (msup6/supA) RNA methylation is dynamically and reversibly regulated by methyl-transferases ("writers"), binding proteins ("readers"), and demethylases ("erasers"). The msup6/supA is restored to adenosine and thus to achieve demethylation modification. The abnormality of msup6/supA epigenetic modification in cancer has been increasingly attended. However, we are rarely aware of its diagnostic, progressive and prognostic performance in lung adenocarcinoma (LUAD). Methods and Results: The expression of 13 widely reported msup6/supA RNA regulators in LUAD and normal samples were systematically analyzed. There were 12 msup6/supA RNA methylation genes displaying aberrant expressions, and an 11-gene diagnostic score model was finally built (Diagnostic score =0.033*KIAA1429+0.116*HNRNPC+0.115*RBM15-0.067* METTL3-0.048*ZC3H13-0.221*WTAP+0.213*YTHDF1-0.132*YTHDC1-0.135* FTO+0.078*YTHDF2+0.014*ALKBH5). Receiver operating characteristic (ROC) analysis was performed to demonstrate superiority of the diagnostic score model (Area under the curve (AUC) was 0.996 of training cohort, P0.0001; AUC was 0.971 of one validation cohort-GSE75037, P0.0001; AUC was 0.878 of another validation cohort-GSE63459, P0.0001). In both training and validation cohorts, YTHDC2 was associated with tumor stage (P0.01), while HNRNPC was up expressed in progressed tumor (P0.05). Besides, WTAP, RBM15, KIAA1429, YTHDF1, and YTHDF2 were all up expressed for TP53 mutation. Furthermore, using least absolute shrinkage and selection operator (lasso) regression analysis, a ten-gene risk score model was built. Risk score=0.169*ALKBH5-0.159*FTO+0.581*HNRNPC-0.348* YTHDF2-0.265*YTHDF1-0.123*YTHDC2+0.434*RBM15+0.143*KIAA1429-0.200*WTAP-0.310*METTL3. There existed correlation between the risk score and TNM stage (P0.01), lymph node stage (P0.05), gender (P0.05), living status (P0.001). Univariate and multivariate Cox regression analyses of relevant clinicopathological characters and the risk score revealed risk score was an independent risk factor of lung adenocarcinoma (HR: 2.181, 95%CI (1.594-2.984), P0.001). Finally, a nomogram was built to facilitate clinicians to predict outcome. Conclusions: msup6/supA epigenetic modification took part in the progression, and provided auxiliary diagnosis and prognosis of LUAD.? The author(s).
机译:背景:N6-甲基腺苷(m 6 a)RNA甲基化由甲基转移酶(“作者”),结合蛋白质(“读者”)和去甲基酶(“橡皮擦”)动态和可逆地调节。 M 6 a恢复为腺苷,从而达到去甲基化改性。越来越多地参加M 6 癌症的表观遗传改性。但是,我们很少了解其在肺腺癌(Luad)中的诊断,逐步和预后性能。方法和结果:13种广泛报道的M 6 水路中的RNA调节剂和正常样品的表达得到了系统地分析。展示异常表达的RNA甲基化基因有12米 6,最后构建了11-基因诊断得分模型(诊断得分= 0.033 * Kiaa1429 + 0.116 * HNRNPC + 0.115 * RBM15-0.067 * METTL3 -0.048 * ZC313-0.221 * WTAP + 0.213 * YTHDF1-0.132 * YTHDC1-0.135 * FTHDC1-0.135 * FTHDC10.078 * YTHDF2 + 0.014 * ALKBH5)。接收器操作特征(ROC)分析进行了展示诊断得分模型的优越性(曲线下的区域(AUC)为0.996的培训队列,P <0.0001; AUC为0.971的一个验证COHORT-GSE75037,P <0.0001; AUC是0.878的另一种验证COHORT-GSE63459,P <0.0001)。在培训和验证队列中,YTHDC2与肿瘤阶段相关(P <0.01),而HNRNPC在进行的肿瘤中表达(P <0.05)。此外,WTAP,RBM15,KIAA1429,YTHDF1和YTHDF2针对TP53突变表达。此外,使用最小绝对收缩和选择操作员(套索)回归分析,建立了一个十基因风险评分模型。风险得分= 0.169 * arkBH5-0.159 * FTO + 0.581 * HNRNPC-0.348 * YTHDF2-0.265 * YTHDF1-0.123 * YTHDC2 + 0.434 * RBM15 + 0.143 * KIAA1429-0.200 * WTAP-0.310 * METTL3。风险评分和TNM阶段之间存在相关性(P <0.01),淋巴结阶段(P <0.05),性别(P <0.05),生活状态(P <0.001)。相关临床病理特征的单变量和多元COX回归分析和风险评分显示出风险评分是肺腺癌的独立危险因素(HR:2.181,95%CI(1.594-2.984),P <0.001)。最后,建立了一个探测图,以促进临床医生预测结果。结论:M 6 表观遗传修饰参与了进展,并提供了管道的辅助诊断和预后。作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号